

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

For the quarterly period ended March 30, 2024

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File Number: 01-14010

**Waters Corporation**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**13-3668640**  
(I.R.S. Employer  
Identification No.)

**34 Maple Street**  
**Milford, Massachusetts 01757**  
(Address, including zip code, of principal executive offices)

**(508) 478-2000**  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	WAT	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13(a) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). No ☒

Indicate the number of shares outstanding of the registrant’s common stock as of May 3, 2024: 59,300,000

---

---

---

## **Table of Contents**

# **WATERS CORPORATION AND SUBSIDIARIES**

## **QUARTERLY REPORT ON FORM 10-Q**

### **INDEX**

#### **PART**

#### **I FINANCIAL INFORMATION**

Item

1. [Financial Statements](#)

[Consolidated Balance Sheets \(unaudited\) as of March 30, 2024 and December 31, 2023](#)

[Consolidated Statements of Operations \(unaudited\) for the three months ended March 30, 2024](#)

[Consolidated Statements of Comprehensive Income \(unaudited\) for the three months ended March 30, 2024](#)

[Consolidated Statements of Cash Flows \(unaudited\) for the three months ended March 30, 2024](#)

[Consolidated Statements of Stockholders' Equity \(unaudited\) for the three months ended March 30, 2024](#)

[Condensed Notes to Consolidated Financial Statements \(unaudited\)](#)

Item

2. [Management's Discussion and Analysis of Financial Condition and Results of Operations](#)

Item

3. [Quantitative and Qualitative Disclosures About Market Risk](#)

Item

4. [Controls and Procedures](#)

#### **PART**

#### **II OTHER INFORMATION**

Item

1. [Legal Proceedings](#)

Item

1A. [Risk Factors](#)

Item

2. [Unregistered Sales of Equity Securities and Use of Proceeds](#)

Item

5. [Other Information](#)

Item

6. [Exhibits](#)

[Signature](#)

---

## [Table of Contents](#)

### Item 1: Financial Statements

#### WATERS CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (unaudited)

	March 30, 2024	Deco
	(In thousands, except per share amounts)	
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 337,290	\$
Investments	923	
Accounts receivable, net	626,329	
Inventories	538,634	
Other current assets	139,782	
Total current assets	1,642,958	
Property, plant and equipment, net	633,594	
Intangible assets, net	611,147	
Goodwill	1,297,826	
Operating lease assets	81,065	
Other assets	242,374	
Total assets	\$ 4,508,964	\$
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Notes payable and debt	\$ 50,000	\$
Accounts payable	86,219	
Accrued employee compensation	65,098	
Deferred revenue and customer advances	336,718	
Current operating lease liabilities	26,879	
Accrued income taxes	120,520	
Accrued warranty	10,853	
Other current liabilities	152,172	
Total current liabilities	848,459	
Long-term liabilities:		
Long-term debt	2,005,761	
Long-term portion of retirement benefits	48,977	
Long-term income tax liabilities	137,439	
Long-term operating lease liabilities	55,927	
Other long-term liabilities	155,876	
Total long-term liabilities	2,403,980	
Total liabilities	3,252,439	
Commitments and contingencies (Notes 6, 7 and 9)		
Stockholders' equity:		
Preferred stock, par value \$0.01 per share, 5,000 shares authorized, none issued at March 30, 2024 and December 31, 2023	—	
Common stock, par value \$0.01 per share, 400,000 shares authorized, 162,882 and 162,709 shares issued, 59,310 and 59,176 shares outstanding at March 30, 2024 and December 31, 2023, respectively	1,629	
Additional paid-in capital	2,291,103	
Retained earnings	9,253,017	

Treasury stock, at cost, 103,572 and 103,533 shares at March 30, 2024 and December 31, 2023, respectively	(10,147,341 )	
Accumulated other comprehensive loss	(141,883 )	
Total stockholders' equity	1,256,525	
Total liabilities and stockholders' equity	\$ 4,508,964	\$

The accompanying notes are an integral part of the interim consolidated financial statements.

[Table of Contents](#)

**WATERS CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(unaudited)**

	<b>Three Months Ended</b>
	<b>March 30, 2024</b>
	<b>(In thousands, except per share amounts)</b>
Revenues:	
Product sales	\$ 376,151
Service sales	260,688
Total net sales	636,839
Costs and operating expenses:	
Cost of product sales	153,182
Cost of service sales	108,604
Selling and administrative expenses	174,536
Research and development expenses	44,595
Purchased intangibles amortization	11,834
Litigation provision	10,242
Total costs and operating expenses	502,993
Operating income	133,846
Other income, net	2,259
Interest expense	(25,520)
Interest income	4,271
Income before income taxes	114,856
Provision for income taxes	12,660
Net income	\$ 102,196
Net income per basic common share	\$ 1.73
Weighted-average number of basic common shares	59,232
Net income per diluted common share	\$ 1.72
Weighted-average number of diluted common shares and equivalents	59,431

The accompanying notes are an integral part of the interim consolidated financial statements.

---

[Table of Contents](#)

**WATERS CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**(unaudited)**

	<b>Three Month</b>
	<b>March 30, 2024</b>
	<b>(In thousands)</b>
Net income	\$ 102,196
Other comprehensive (loss) income:	
Foreign currency translation	(9,540)
Unrealized gains on derivative instruments before reclassifications	2,405
Amounts reclassified to interest income	(297)
Unrealized gains on derivative instruments before income taxes	2,108
Income tax expense	(506)
Unrealized gains on derivative instruments, net of tax	1,602
Retirement liability adjustment before reclassifications	332
Amounts reclassified to other income	(117)
Retirement liability adjustment before income taxes	215
Income tax expense	(40)
Retirement liability adjustment, net of tax	175
Other comprehensive (loss) income	(7,763)
Comprehensive income	\$ 94,433

The accompanying notes are an integral part of the interim consolidated financial statements.

## [Table of Contents](#)

### WATERS CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

	Three Month March 30, 2024
Cash flows from operating activities:	(In thousands)
Net income	\$ 102,196
Adjustments to reconcile net income to net cash provided by operating activities:	
Stock-based compensation	10,913
Deferred income taxes	4,453
Depreciation	22,129
Amortization of intangibles	26,385
Change in operating assets and liabilities:	
Decrease in accounts receivable	62,592
Increase in inventories	(28,309)
Increase in other current assets	(4,707)
Decrease in other assets	7,369
Decrease in accounts payable and other current liabilities	(18,418)
Increase in deferred revenue and customer advances	85,901
(Decrease) increase in other liabilities	(7,634)
Net cash provided by operating activities	262,870
Cash flows from investing activities:	
Additions to property, plant, equipment and software capitalization	(28,655)
Investments in unaffiliated companies	(1,064)
Purchases of investments	(923)
Maturities and sales of investments	898
Net cash used in investing activities	(29,744)
Cash flows from financing activities:	
Proceeds from debt issuances	—
Payments on debt	(300,000)
Proceeds from stock plans	13,932
Purchases of treasury shares	(13,089)
Proceeds from derivative contracts	6,981
Net cash used in financing activities	(292,176)
Effect of exchange rate changes on cash and cash equivalents	1,264
(Decrease) increase in cash and cash equivalents	(57,786)
Cash and cash equivalents at beginning of period	395,076
Cash and cash equivalents at end of period	\$ 337,290

The accompanying notes are an integral part of the interim consolidated financial statements.



[Table of Contents](#)

**WATERS CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**  
(unaudited, in thousands)

	<b>Number of Common Shares</b>	<b>Common Stock</b>	<b>Additional Paid-In Capital</b>	<b>Retained Earnings</b>	<b>Treasury Stock</b>	<b>Accumulated Other Comprehensive Loss</b>
Balance December 31, 2022	162,425	\$ 1,624	\$ 2,199,824	\$ 8,508,587	\$ (10,063,975)	\$ (141,572)
Net income	—	—	—	140,923	—	—
Other comprehensive income	—	—	—	—	—	8,776
Issuance of common stock for employees:						
Employee Stock Purchase Plan	8	—	2,000	—	—	—
Stock options exercised	6	—	969	—	—	—
Treasury stock	—	—	—	—	(69,505)	—
Stock-based compensation	111	2	12,170	—	—	—
Balance April 1, 2023	<u>162,550</u>	<u>\$ 1,626</u>	<u>\$ 2,214,963</u>	<u>\$ 8,649,510</u>	<u>\$ (10,133,480)</u>	<u>\$ (132,796)</u>
	<b>Number of Common Shares</b>	<b>Common Stock</b>	<b>Additional Paid-In Capital</b>	<b>Retained Earnings</b>	<b>Treasury Stock</b>	<b>Accumulated Other Comprehensive Loss</b>
Balance December 31, 2023	162,709	\$ 1,627	\$ 2,266,265	\$ 9,150,821	\$ (10,134,252)	\$ (134,120)
Net income	—	—	—	102,196	—	—
Other comprehensive loss	—	—	—	—	—	(7,763)
Issuance of common stock for employees:						
Employee Stock Purchase Plan	8	—	1,996	—	—	—
Stock options exercised	51	1	12,551	—	—	—
Treasury stock	—	—	—	—	(13,089)	—
Stock-based compensation	<u>114</u>	<u>1</u>	<u>10,291</u>	<u>—</u>	<u>—</u>	<u>—</u>

Balance March 30, 2024	<u><u>162,882</u></u>	<u><u>\$ 1,629</u></u>	<u><u>\$ 2,291,103</u></u>	<u><u>\$ 9,253,017</u></u>	<u><u>\$ (10,147,341)</u></u>	<u><u>\$ (141,883)</u></u>
---------------------------	-----------------------	------------------------	----------------------------	----------------------------	-------------------------------	----------------------------

The accompanying notes are an integral part of the consolidated financial statements.

---

## [Table of Contents](#)

### **CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)**

#### **1 Basis of Presentation and Summary of Significant Accounting Policies**

Waters Corporation (the “Company,” “we,” “our,” or “us”), a global leader in analytical instruments and solutions, pioneered innovations in chromatography, mass spectrometry and thermal analysis serving life, material and physical sciences for more than 65 years. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLC” and together with HPLC to as “LC”) and mass spectrometry (“MS”) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. These systems are sold as complementary products that are frequently employed together (“LC-MS”) and sold as integrated instruments using common software platforms. LC is a standard technique and is utilized in a broad range of industrial applications to identify, monitor and measure the chemical, physical and biological composition of materials, and to purify mixtures of compounds. MS technology, principally in conjunction with chromatography, is employed in drug discovery and development, including clinical trial testing, the analysis of proteins in disease processes (known as “proteomics”), nutritional safety analysis and environmental testing. LC-MS instruments combine a liquid phase sample introduction and separation system with mass spectrometric compound identification and quantification. In addition, the Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments throughout its Instruments product line. These instruments are used in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals and viscous liquids for various industrial, consumer goods and food products, as well as for life science research. The Company is also a developer and supplier of advanced interface products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

On May 16, 2023, the Company completed the acquisition of Wyatt Technology, LLC and its three operating subsidiaries, Wyatt Technology Europe GmbH, Wyatt Technology France and Wyatt Technology UK Ltd. (collectively, “Wyatt”), for a total purchase price of \$1.3 billion in cash. Wyatt is a pioneer in innovative light scattering and fractionation instruments, software, accessories and services. The acquisition will expand Waters’ portfolio and increase exposure to large molecule applications. The Company financed this transaction with a combination of cash on its balance sheet and borrowings under its Credit Facility (as defined below). The Company’s financial results for the three months ended March 30, 2024 include the financial results of Wyatt. The Company’s financial results for the three months ended April 1, 2023 do not include any of the financial results of Wyatt since the closing of the acquisition occurred in the second fiscal quarter of 2023. In addition, the Company has completed the purchase price allocation for the Wyatt acquisition and there were no material changes as compared to the Company’s preliminary purchase price allocation for the Wyatt acquisition.

The Company’s interim fiscal quarter typically ends on the thirteenth Saturday of each quarter. Since the Company’s fiscal year end is December 31, the first and fourth fiscal quarters may have more or less than thirteen calendar months. The Company’s first fiscal quarters for 2024 and 2023 ended on March 30, 2024 and April 1, 2023, respectively.

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the instructions in Form 10-Q and do not include all of the information and footnote disclosures required for annual financial statements prepared in accordance with generally accepted accounting principles (“U.S. GAAP”) in the United States of America. The consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are wholly owned. All inter-company balances and transactions have been eliminated.

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the timing of the disclosure of contingent liabilities at the dates of the financial statements. Actual amounts may differ from those estimates under different assumptions or conditions.

It is management’s opinion that the accompanying interim consolidated financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim period. The interim consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the U.S. Securities and Exchange Commission (“SEC”) on February 27, 2024.



---

## [Table of Contents](#)

### **CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)**

#### **Risks and Uncertainties**

The Company is subject to risks common to companies in the analytical instrument industry, including, but not limited to, global economic and financial market conditions, fluctuations in foreign currency exchange rates, fluctuations in customer demand, development by its competitors of new technological innovations, costs of developing new technologies, levels of debt and debt service requirements, risk of disruption, dependence on key personnel, and litigation of proprietary technology, shifts in taxable income between tax jurisdictions and compliance with the regulations of the U.S. Food and Drug Administration and similar foreign regulatory authorities and agencies.

#### **Translation of Foreign Currencies**

The functional currency of each of the Company's foreign operating subsidiaries is the local currency of its domicile, except for the Company's subsidiaries in Hong Kong, Singapore and the Cayman Islands, where the underlying transactional cash flows are denominated in currencies other than the respective local currencies. The functional currency of the Hong Kong, Singapore and Cayman Islands subsidiaries is the U.S. dollar, which is used to measure the respective entity's cash flows.

For the Company's foreign operations, assets and liabilities are translated into U.S. dollars at exchange rates in effect on the balance sheet date, while revenues and expenses are translated at average exchange rates prevailing during the respective period. Any resulting translation gains or losses are included in accumulated other comprehensive income in the consolidated balance sheets.

#### **Cash, Cash Equivalents and Investments**

Cash equivalents represent highly liquid investments, with original maturities of 90 days or less, while investments with longer maturities are classified as investments. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. At March 30, 2024 and December 31, 2023, \$305 million out of \$338 million and \$321 million out of \$396 million, respectively, of the Company's total cash, cash equivalents and investments were held by foreign subsidiaries. In addition, \$239 million out of \$338 million and \$233 million out of \$396 million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at March 30, 2024 and December 31, 2023.

#### **Accounts Receivable and Allowance for Credit Losses**

Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The Company has no use of rebates and other cash considerations payable to customers and, as a result, the transaction price does not have any material variable consideration. The Company does not consider there to be significant concentrations of credit risk with respect to trade receivables due to the short-term nature of the balances, the Company having a large and diverse customer base, and the Company having a strong historical experience in collecting receivables with minimal defaults. As a result, credit risk is considered low across territories and trade receivables are considered to be a single class of financial asset. The allowance for credit losses is based on a number of factors and is calculated by applying a historical loss rate to trade receivable aging balances to estimate the reserve balance along with an additional adjustment for any specific receivables with known or anticipated credit losses affecting the likelihood of recovery. Past due balances with a probability of default based on historical data and relevant available forward-looking information are included in the specific adjustment. The historical loss rate is reviewed on at least an annual basis and the allowance for credit losses is reviewed quarterly for any required adjustments. The Company does not have any off-balance sheet credit exposure related to its customers.

Trade receivables related to instrument sales are collateralized by the instrument that is sold. If there is a default related to a receivable that is collateralized, then the fair value of the collateral is calculated and

the cost to re-possess, refurbish and re-sell the instrument. This adjusted fair value is compared to the re balance and the difference would be recorded as the expected credit loss.

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

The following is a summary of the activity of the Company's allowance for credit losses for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	Balance at Beginning of Period	Additions	Deductions and Other	Balance at End of Period
Allowance for Credit Losses				
March 30, 2024	\$ 19,335	\$ 991	\$ (5,461 )	\$ 14,865
April 1, 2023	\$ 14,311	\$ 1,572	\$ (1,028 )	\$ 14,855

### Fair Value Measurements

In accordance with the accounting standards for fair value measurements and disclosures, certain of the assets and liabilities are measured at fair value on a recurring basis as of March 30, 2024 and December 31, 2023. Fair values determined by Level 1 inputs utilize observable data, such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points for which there is no market data, which require the reporting entity to develop its own assumptions.

The following table represents the Company's assets and liabilities measured at fair value on a recurring basis as of March 30, 2024 (in thousands):

	Total at March 30, 2024	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Time deposits	\$ 923	\$ —	\$ 923	\$ —
Waters 401(k) Restoration Plan assets	30,791	30,791	—	—
Interest rate cross-currency swap agreements	7,642	—	7,642	—
Total	<u>\$ 39,356</u>	<u>\$ 30,791</u>	<u>\$ 8,565</u>	<u>\$ —</u>
Liabilities:				
Foreign currency exchange contracts	\$ 75	\$ —	\$ 75	\$ —
Interest rate cross-currency swap agreements	5,510	—	5,510	—
Interest rate swap cash flow hedge	865	—	865	—
Total	<u>\$ 6,450</u>	<u>\$ —</u>	<u>\$ 6,450</u>	<u>\$ —</u>

## Table of Contents

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

The following table represents the Company's assets and liabilities measured at fair value on a recurring December 31, 2023 (in thousands):

	Total at December 31, 2023	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	S Un
<b>Assets:</b>				
Time deposits	\$ 898	\$ —	\$ 898	\$
Waters 401(k) Restoration Plan assets	28,995	28,995	—	
Foreign currency exchange contracts	183	—	183	
Interest rate cross-currency swap agreements	4,835	—	4,835	
Total	<u>\$ 34,911</u>	<u>\$ 28,995</u>	<u>\$ 5,916</u>	<u>\$</u>
<b>Liabilities:</b>				
Foreign currency exchange contracts	207	—	207	
Interest rate cross-currency swap agreements	13,384	—	13,384	
Interest rate swap cash flow hedge	2,974	—	2,974	
Total	<u>\$ 16,565</u>	<u>\$ —</u>	<u>\$ 16,565</u>	<u>\$</u>

#### Fair Value of 401(k) Restoration Plan Assets

The 401(k) Restoration Plan is a nonqualified defined contribution plan and the assets were held in registered funds and have been classified as Level 1. The fair values of the assets in the plan are determined through observable sources from daily quoted prices on nationally recognized securities exchanges.

#### Fair Value of Cash Equivalents, Investments, Foreign Currency Exchange Contracts, Interest Rate Cross-Swap Agreements and Interest Rate Swap Cash Flow Hedges

The fair values of the Company's cash equivalents, investments, foreign currency exchange contracts, interest rate cross-currency swap agreements and interest rate swap cash flow hedges are determined through market observable sources and have been classified as Level 2. These assets and liabilities have been initially valued at transaction price and subsequently valued, typically utilizing third-party pricing services. The pricing services use inputs to determine value, including reportable trades, benchmark yields, credit spreads, broker/dealer quotes, spot rates and other industry and economic events. The Company validates the prices provided by third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources.

#### Fair Value of Other Financial Instruments

The Company's accounts receivable and accounts payable are recorded at cost, which approximates fair value due to their short-term nature. The carrying value of the Company's variable interest rate debt approximates fair value due to the variable nature of the interest rate. The carrying value of the Company's fixed interest rate debt was \$1.0 billion at both March 30, 2024 and December 31, 2023. The fair value of the Company's fixed interest rate debt was determined using discounted cash flow models, based on estimated current rates offered for similar debt under current market conditions.



conditions for the Company. The fair value of the Company's fixed interest rate debt was estimated to be both March 30, 2024 and December 31, 2023, using Level 2 inputs.

#### Derivative Transactions

The Company is a global company that operates in over 35 countries and, as a result, the Company's net sales, operating expenses and balance sheet amounts are significantly impacted by fluctuations in foreign exchange rates. The Company is exposed to currency price risk on foreign currency exchange rate fluctuations. The Company translates its non-U.S. dollar foreign subsidiaries' financial statements into U.S. dollars and when any of its subsidiaries purchase or sell products or services in a currency other than its own currency.

---

## [Table of Contents](#)

### **CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con**

The Company's principal strategies in managing exposures to changes in foreign currency exchange rates (1) naturally hedge the foreign-currency-denominated liabilities on the Company's balance sheet against assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of operations by hedging the variability in the movement of foreign currency exchange rates on a portion of euro-denominated and yen-denominated net asset investments. The Company presents the derivative transaction and financing activities in the statement of cash flows.

#### Foreign Currency Exchange Contracts

The Company does not specifically enter into any derivatives that hedge foreign-currency-denominated assets, liabilities or commitments on its balance sheet, other than a portion of certain third-party accounts receivable and accounts payable, and the Company's net worldwide intercompany receivables and payables, which are eliminated in consolidation. The Company periodically aggregates its net worldwide balances by currency and then enters into foreign currency exchange contracts that mature within 90 days to hedge a portion of the remaining balances to minimize some of the Company's currency price risk exposure. The foreign currency exchange contracts are designated for hedge accounting treatment. Principal hedged currencies include the euro, Japanese yen, Mexican peso and Brazilian real.

#### Cash Flow Hedges

The Company's Credit Facility is a variable borrowing and has interest payments based on a contractually specified interest rate index. The contractually specified index on the Credit Facility is the 3-month Term SOFR. The interest payments create interest risk for the Company as interest payments will fluctuate based on changes in the contractually specified interest rate index over the life of the Credit Facility. In order to reduce interest risk, the Company enters into interest rate swaps that will effectively lock-in the forecasted interest payments on the Credit Facility over its term. The interest rate swaps represent cash flow hedges and are assessed for hedge effectiveness each reporting period. When the hedge relationship is highly effective at achieving offsetting changes in cash flows, the Company will record the entire change in fair value of the interest rate swaps in accumulated other comprehensive loss. The amount in accumulated other comprehensive loss is reclassified to income in the current period if the underlying transaction impacts consolidated income. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive loss will be reclassified to income in the current period. Interest settlements due to benchmark interest rate changes are recorded in interest income or interest expense. For the three months ended March 30, 2024, the Company did not have any cash flow hedges that were deemed ineffective.

#### Interest Rate Cross-Currency Swap Agreements

As of March 30, 2024, the Company had entered into interest rate cross-currency swap derivative agreements with durations up to three years with an aggregate notional value of \$625 million to hedge the variability in the foreign currency exchange rates on a portion of its euro-denominated and yen-denominated net asset investments. Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency exchange rates are recorded in the currency translation adjustment in other comprehensive income and remain in accumulated other comprehensive loss in stockholders' equity until the sale or substantial liquidation of the foreign operations. The difference between the interest rate received and paid under the interest rate cross-currency swap derivative agreement is recorded in interest income in the statement of operations.

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

The Company's foreign currency exchange contracts, interest rate cross-currency swap agreements and swap agreements designated as cash flow hedges are included in the consolidated balance sheets are classified as follows (in thousands):

	March 30, 2024		December 31, 2023
	Notional	Fair Value	Notional
Foreign currency exchange contracts:			
Other current assets	\$ 5,000	\$ —	\$ 24,155
Other current liabilities	\$ 35,314	\$ 75	\$ 16,000
Interest rate cross-currency swap agreements:			
Other assets	\$ 285,000	\$ 7,642	\$ 220,000
Other liabilities	\$ 340,000	\$ 5,510	\$ 405,000
Accumulated other comprehensive income (loss)		\$ 6,942	
Interest rate swap cash flow hedges:			
Other liabilities	\$ 100,000	\$ 865	\$ 100,000
Accumulated other comprehensive loss		\$ (865)	

The following is a summary of the activity included in the consolidated statements of operations and statement of other comprehensive income related to the foreign currency exchange contracts, interest rate cross-currency swap agreements and interest rate swap agreements designated as cash flow hedges (in thousands):

	Financial Statement Classification	Three Months Ended	
		March 30, 2024	April 1, 2023
Foreign currency exchange contracts:			
Realized gains on closed contracts	Cost of sales	\$ 257	\$ 30
Unrealized losses on open contracts	Cost of sales	(51)	(78)
Cumulative net pre-tax gains (losses)	Cost of sales	\$ 206	\$ (48)
Interest rate cross-currency swap agreements:			
Interest earned	Interest income	\$ 2,537	\$ 2,655
Unrealized gains (losses) on contracts, net	Accumulated other comprehensive loss	\$ 14,917	\$ (7,256)
Interest rate swap cash flow hedges:			
Interest earned	Interest income	\$ 296	\$ —
Unrealized gains on open contracts	Accumulated other comprehensive loss	\$ 2,109	\$ —

---

## [Table of Contents](#)

### **CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con**

#### Stockholders' Equity

In December 2023, the Company's Board of Directors authorized the extension of its existing share repurchase program through January 21, 2025. The Company's remaining authorization is \$1.0 billion. During the three months ended April 1, 2023, the Company repurchased 0.2 million shares of the Company's outstanding common stock at a cost of \$58 million under the Company's share repurchase program. The Company did not make any open market repurchases in 2024. In addition, the Company repurchased \$13 million and \$11 million of common stock upon the vesting of restricted stock units during the three months ended March 30, 2024 and April 1, 2023, respectively.

---

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

#### Product Warranty Costs

The Company accrues estimated product warranty costs at the time of sale, which are included in cost of consolidated statements of operations. While the Company engages in extensive product quality program processes, including actively monitoring and evaluating the quality of its component suppliers, the Company's obligation is affected by product failure rates, material usage and service delivery costs incurred in correcting product failure. The amount of the accrued warranty liability is based on historical information, such as past experience, product failure rates, number of units repaired and estimated costs of material and labor. The Company reviews the accrual for reasonableness at least quarterly.

The following is a summary of the activity of the Company's accrued warranty liability for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	<b>Balance at Beginning of Period</b>	<b>Accruals for Warranties</b>	<b>Settlements Made</b>
Accrued warranty liability:			
March 30, 2024	\$ 12,050	\$ 480	\$ (1,677)
April 1, 2023	\$ 11,949	\$ 2,177	\$ (1,815)

#### Restructuring

In March 2024, the Company had a reduction in workforce that impacted approximately 2% of the employees in China due to the significant decline in sales resulting from lower customer demand, which resulted in incurring approximately \$8 million of severance-related costs. During the first quarter of 2024, the Company incurred \$8 million of severance-related costs in connection with the workforce reductions that occurred in March 2023, with the majority of the remaining costs to be paid in the second quarter of 2024. The accrued restructuring expense was \$8 million at both March 30, 2024 and December 31, 2023 and were included in other current liabilities on the consolidated balance sheets.

## 2 Revenue Recognition

The Company's deferred revenue liabilities in the consolidated balance sheets consist of the obligation on service contracts and customer payments received in advance, prior to transfer of control of the instrument. The Company records deferred revenue primarily related to its service contracts, where consideration is billed at the beginning of the service period.

The following is a summary of the activity of the Company's deferred revenue and customer advances for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	<b>March 30, 2024</b>	<b>April 1, 2023</b>
Balance at the beginning of the period	\$ 323,516	\$ 285,175
Recognition of revenue included in balance at beginning of the period	(103,996)	(105,222)
Revenue deferred during the period, net of revenue recognized	187,525	193,286
Balance at the end of the period	<u>\$ 407,045</u>	<u>\$ 373,239</u>

The Company classified \$70 million and \$67 million of deferred revenue and customer advances in other liabilities at March 30, 2024 and December 31, 2023, respectively.



---

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

The amount of deferred revenue and customer advances equals the transaction price allocated to unfulfilled performance obligations for the period presented. Such amounts are expected to be recognized in the future (in thousands):

	March 30, 2024
Deferred revenue and customer advances expected to be recognized in:	
One year or less	\$ 336,718
13-24 months	42,162
25 months and beyond	28,165
Total	<u>\$ 407,045</u>

### 3 Marketable Securities

The Company's marketable securities within cash equivalents and investments included in the consolidated balance sheets consist of time deposits that mature in one year or less with an amortized cost and a fair value of both March 30, 2024 and December 31, 2023.

### 4 Inventories

Inventories are classified as follows (in thousands):

	March 30, 2024	December 31, 2023
Raw materials	\$ 241,744	\$ 233,952
Work in progress	23,825	20,198
Finished goods	273,065	262,086
Total inventories	<u>\$ 538,634</u>	<u>\$ 516,236</u>

### 5 Goodwill and Other Intangibles

The carrying amount of goodwill was \$1.3 billion at both March 30, 2024 and December 31, 2023.

The Company's intangible assets included in the consolidated balance sheets are detailed as follows (dollars in thousands):

	March 30, 2024			December 31, 2023	
	Gross Carrying Amount	Accumulated Amortization	Weighted-Average Amortization Period	Gross Carrying Amount	Accumulated Amortization
Capitalized software	\$ 655,433	\$ 495,177	5 years	\$ 660,273	\$ 495,317
Purchased intangibles	612,382	207,620	10 years	614,357	197,154
Trademarks	9,680	—	—	9,680	—
Licenses	14,673	8,698	7 years	14,798	8,429

Patents and other intangibles	<u>113,028</u>	<u>82,554</u>	8 years	<u>111,962</u>	<u>80,983</u>
Total	<u>\$ 1,405,196</u>	<u>\$ 794,049</u>	7 years	<u>\$ 1,411,070</u>	<u>\$ 781,883</u>

The Company capitalized \$10 million and \$14 million of intangible assets in the three months ended March 30, 2024 and April 1, 2023, respectively. The gross carrying value of intangible assets and accumulated amortization of intangible assets decreased by \$16 million and \$14 million, respectively, in the three months ended March 30, 2024 to the effects of foreign currency translation. Amortization expense for intangible assets was \$26 million and \$12 million for the three months ended March 30, 2024 and April 1, 2023, respectively. Amortization expense for intangible assets is estimated to be \$108 million per year for each of the next five years.



---

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

#### 6 Debt

The Company has a five-year, \$2.0 billion revolving credit facility (the “Credit Facility”) that matures in 2026. As of March 30, 2024 and December 31, 2023, the Credit Facility had a total of \$0.8 billion and \$1.3 billion outstanding, respectively.

The interest rates applicable under the Credit Facility are, at the Company’s option, equal to either the applicable base rate (which is a rate per annum equal to the greatest of (1) the prime rate in effect on such day, (2) the Federal Reserve Bank of New York Rate on such day plus 1/2 of 1% per annum and (3) the adjusted Term SOFR rate for a one-month interest period as published two U.S. Government Securities Business Days prior to such day (or if not a U.S. Government Securities Business Day, the immediately preceding U.S. Government Securities Business Day) plus 1% annum) or the applicable 1, 3 or 6 month adjusted Term SOFR or EURIBO rate for euro-denominated loans. In each case, plus an interest rate margin based upon the Company’s leverage ratio, which can range between 50 and 100 basis points for alternate base rate loans and between 80 and 112.5 basis points for Term SOFR or EURIBO loans. The facility fee on the Credit Facility ranges between 7.5 and 25 basis points per annum, based on the leverage ratio and the amount of the revolving facility commitments and the outstanding term loan. The Credit Facility requires the Company comply with an interest coverage ratio test of not less than 3.50:1 as of the end of any fiscal quarter and a leverage ratio test of not more than 3.50:1 as of the end of any fiscal quarter. In addition, the Credit Facility includes negative covenants, affirmative covenants, representations and warranties and events of default that are customary for investment grade credit facilities.

As of both March 30, 2024 and December 31, 2023, the Company had a total of \$1.3 billion of outstanding senior unsecured notes. Interest on the fixed rate senior unsecured notes is payable semi-annually each year. Interest on the floating rate senior unsecured notes is payable quarterly. The Company may prepay all or some of the senior unsecured notes at any time in an amount not less than 10% of the aggregate principal amount outstanding. In the event of a change in control of the Company (as defined in the note purchase agreement), the Company may be required to prepay the senior unsecured notes at a price equal to 100% of the principal amount thereof, plus accrued interest. These senior unsecured notes require that the Company comply with an interest coverage ratio test of not less than 3.50:1 for any period of four consecutive fiscal quarters and a leverage ratio test of not more than 3.50:1 as of the end of any fiscal quarter. In addition, these senior unsecured notes include customary negative covenants, affirmative covenants, representations and warranties and events of default.

The Company had the following outstanding debt at March 30, 2024 and December 31, 2023 (in thousands):

	<b>March 30, 2024</b>	<b>December 31, 2023</b>
Senior unsecured notes - Series G - 3.92%, due June 2024	50,000	50,000
Total notes payable and debt, current	50,000	50,000
Senior unsecured notes - Series K - 3.44%, due May 2026	160,000	160,000
Senior unsecured notes - Series L - 3.31%, due September 2026	200,000	200,000
Senior unsecured notes - Series M - 3.53%, due September 2029	300,000	300,000
Senior unsecured notes - Series N - 1.68%, due March 2026	100,000	100,000
Senior unsecured notes - Series O - 2.25%, due March 2031	400,000	400,000
Senior unsecured notes - Series P - 4.91%, due May 2028	50,000	50,000
Senior unsecured notes - Series Q - 4.91%, due May 2030	50,000	50,000

Credit agreement	750,000	1,050,000
Unamortized debt issuance costs	(4,239)	(4,487)
Total long-term debt	2,005,761	2,305,513
Total debt	<u>\$ 2,055,761</u>	<u>\$ 2,355,513</u>

As of March 30, 2024 and December 31, 2023, the Company had a total amount available to borrow under the Credit Facility of \$1.2 billion and \$0.9 billion, respectively, after outstanding letters of credit. The weighted-average interest rates applicable to the senior unsecured notes and credit agreement borrowings collectively were 4.42% and 4.42% as of March 30, 2024 and December 31, 2023, respectively. As of March 30, 2024, the Company was in compliance with all debt covenants.

---

## [Table of Contents](#)

### **CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con**

The Company and its foreign subsidiaries also had available short-term lines of credit totaling \$112 million and \$114 million at March 30, 2024 and December 31, 2023, respectively, for the purpose of short-term borrowing and issuance of commercial guarantees. None of the Company's foreign subsidiaries had outstanding short-term debt as of March 30, 2024 or December 31, 2023.

#### **7 Income Taxes**

The four principal jurisdictions in which the Company manufactures are the U.S., Ireland, the U.K. and Singapore, where the statutory tax rates were 21%, 12.5%, 25% and 17%, respectively, as of March 30, 2024. The Company has a Development and Expansion Incentive in Singapore that provides a concessionary income tax rate of 5% for certain types of income for the period April 1, 2021 through March 31, 2026. The effect of applying the concessionary tax rate rather than the statutory tax rate to income arising from qualifying activities in Singapore increased the Company's net income for the three months ended March 30, 2024 and April 1, 2023 by \$2 million and \$1 million, respectively, and increased the Company's net income per diluted share by \$0.03 and \$0.05, respectively.

The Company's effective tax rate for the three months ended March 30, 2024 and April 1, 2023 was 11.0% and 12.5%, respectively. The income tax provision includes a \$1 million and a \$2 million income tax benefit related to compensation for the three months ended March 30, 2024 and April 1, 2023, respectively. The remaining difference between the effective tax rates can primarily be attributed to the impact of discrete tax benefits in the current period and differences in the proportionate amounts of pre-tax income recognized in jurisdictions with different effective tax rates.

The Company accounts for its uncertain tax return positions in accordance with the accounting standards for uncertain tax positions, which require financial statement reporting of the expected future tax consequences of uncertain tax positions on the presumption that all concerned tax authorities possess full knowledge of those tax reporting positions as well as all of the pertinent facts and circumstances, but prohibit any discounting of unrecognized tax liabilities associated with those reporting positions for the time value of money. The Company continues to classify potential penalties related to unrecognized tax benefits as a component of the provision for income taxes.

The Company's gross unrecognized tax benefits, excluding interest and penalties, at March 30, 2024 and December 31, 2023 were \$15 million and \$30 million, respectively. With limited exceptions, the Company is no longer subject to tax examinations in significant jurisdictions for the years ended on or before December 31, 2018. The Company continuously monitors the lapsing of statutes of limitations on potential tax assessments for related changes in the measurement of unrecognized tax benefits, related net interest and penalties, and deferred tax assets and liabilities.

Effective in 2024, various foreign jurisdictions began implementing aspects of the guidance issued by the OECD for Economic Co-operation and Development related to the new Pillar Two system of global minimum tax. Changes in tax law did not have a material impact on the Company's financial position, results of operations or cash flows for the first quarter of 2024. The Company continues to monitor the adoption of the Pillar Two rules in various jurisdictions.

#### **8 Litigation**

From time to time, the Company and its subsidiaries are involved in various litigation matters arising in the course of business. The Company believes it has meritorious arguments in its current litigation matters and any outcome, either individually or in the aggregate, will not be material to the Company's financial position, operations or cash flows. During the three months ended March 30, 2024, the Company recorded \$10 million in litigation settlement provisions and related costs. The accrued patent litigation expense is in other current liabilities on the consolidated balance sheet at March 30, 2024.

#### **9 Other Commitments and Contingencies**

The Company licenses certain technology and software from third parties in the course of ordinary business. Minimum license fees payable under existing license agreements as of March 30, 2024 are immaterial for the periods ended December 31, 2024 and thereafter.

---

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

The Company enters into standard indemnification agreements in its ordinary course of business. Pursuant to these agreements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company's business partners or customers, in connection with patent, copyright or other intellectual property infringement claims by any third party with respect to the Company's products, as well as claims relating to property damage or personal injury resulting from the performance of services by the Company or its subcontractors. The maximum potential amount of future payments the Company may be required to make under these indemnification agreements is unlimited. Historically, the Company's costs incurred in lawsuits or settle claims relating to such indemnity agreements have been minimal and management currently believes the estimated fair value of these agreements is immaterial.

#### 10 Earnings Per Share

Basic and diluted EPS calculations are detailed as follows (in thousands, except per share data):

	Three Months Ended March 30, 2024		
	Net Income (Numerator)	Weighted- Average Shares (Denominator)	Per Share Amount
Net income per basic common share	\$ 102,196	59,232	\$ 1.73
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities	—	199	(0.00)
Net income per diluted common share	<u>\$ 102,196</u>	<u>59,431</u>	<u>\$ 1.72</u>

  

	Three Months Ended April 1, 2023		
	Net Income (Numerator)	Weighted- Average Shares (Denominator)	Per Share Amount
Net income per basic common share	\$ 140,923	59,023	\$ 2.39
Effect of dilutive stock option, restricted stock, performance stock unit and restricted stock unit securities	—	294	(0.00)
Net income per diluted common share	<u>\$ 140,923</u>	<u>59,317</u>	<u>\$ 2.39</u>

For the three months ended March 30, 2024 and April 1, 2023, the Company had approximately 326,000 shares of common stock outstanding and approximately 140,000 stock options that were antidilutive, respectively, due to having higher exercise prices than the Company's average stock price during the applicable period. These securities were not included in the calculation of diluted EPS. The effect of dilutive securities was calculated using the treasury stock method.

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

#### 11 Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are detailed as follows (in thousands):

	Currency Translation	Unrealized Loss on Retirement Plans	Unrealized Loss on Derivative Instruments	Accu O Comp
Balance at December 31, 2023	\$ (128,359)	\$ (3,501)	\$ (2,260)	\$
Other comprehensive income (loss), net of tax	(9,540)	175	1,602	
Balance at March 30, 2024	<u>\$ (137,899)</u>	<u>\$ (3,326)</u>	<u>\$ (658)</u>	<u>\$</u>

#### 12 Business Segment Information

The Company's business activities, for which discrete financial information is available, are regularly re-evaluated by the chief operating decision maker. As a result of this evaluation, the Company determined operating segments: Waters™ and TA™.

The Waters operating segment is primarily in the business of designing, manufacturing, selling and servicing MS instruments, columns and other precision chemistry consumables that can be integrated and used with analytical instruments. Operations of the Wyatt business are part of the Waters operating segment. The TA operating segment is primarily in the business of designing, manufacturing, selling and servicing thermal analysis, calorimetry instruments. The Company's two operating segments have similar economic characteristics; processes; products and services; types and classes of customers; methods of distribution; and regulatory environments. Because of these similarities, the two segments have been aggregated into one reporting unit for financial statement purposes.

Net sales for the Company's products and services are as follows for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	Three Months Ended	
	March 30, 2024	April 1, 2023
Product net sales:		
Waters instrument systems	\$ 191,259	\$ 244,211
Chemistry consumables	134,207	133,515
TA instrument systems	50,685	58,731
Total product sales	376,151	436,457
Service net sales:		
Waters service	236,433	224,349
TA service	24,255	23,868
Total service sales	260,688	248,217
Total net sales	<u>\$ 636,839</u>	<u>\$ 684,674</u>

---

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

Net sales are attributable to geographic areas based on the region of destination. Geographic sales information is presented below for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	Three Months Ended	
	March 30, 2024	April 1, 2023
Net Sales:		
Asia:		
China	\$ 85,745	\$ 116,065
Japan	35,547	46,494
Asia Other	86,267	90,522
Total Asia	207,559	253,081
Americas:		
United States	202,839	202,305
Americas Other	38,332	44,116
Total Americas	241,171	246,421
Europe	188,109	185,172
Total net sales	\$ 636,839	\$ 684,674

Net sales by customer class are as follows for the three months ended March 30, 2024 and April 1, 2023

	Three Months Ended	
	March 30, 2024	April 1, 2023
Pharmaceutical	\$ 374,207	\$ 384,898
Industrial	195,334	209,650
Academic and government	67,298	90,126
Total net sales	\$ 636,839	\$ 684,674

---

## [Table of Contents](#)

### CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) - (Con

Net sales for the Company recognized at a point in time versus over time are as follows for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	Three Months Ended	
	March 30, 2024	April 1, 2023
Net sales recognized at a point in time:		
Instrument systems	\$ 241,944	\$ 241,944
Chemistry consumables	134,207	134,207
Service sales recognized at a point in time (time & materials)	83,325	83,325
Total net sales recognized at a point in time	459,476	459,476
Net sales recognized over time:		
Service and software maintenance sales recognized over time (contracts)	177,363	177,363
Total net sales	\$ 636,839	\$ 636,839

### 13 Recent Accounting Standard Changes and Developments

#### Recently Issued Accounting Standards

There were no additions to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the year ended December 31, 2023. Other amendments to U.S. GAAP that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our condensed consolidated financial statements upon adoption.



---

## [Table of Contents](#)

### **Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operation**

#### **Business Overview**

The Company has two operating segments: Waters™ and TA™. Waters products and services primarily consist of performance liquid chromatography (“HPLC”), ultra-performance liquid chromatography (“UPLC™” and “UHPLC”, referred to as “LC”), mass spectrometry (“MS”), light scattering and field-flow fractionation instruments and precision chemistry consumable products and related services. TA products and services primarily consist of thermal analysis, rheometry and calorimetry instrument systems and service sales. The Company’s products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic and government customers. These customers use the Company’s products to detect, identify, monitor and measure the chemical, physical and biological composition of materials and to predict the suitability and stability of fine chemicals, pharmaceuticals, polymers, metals and viscous liquids in various industrial, consumer goods and healthcare products.

#### **Wyatt Acquisition**

On May 16, 2023, the Company completed the acquisition of Wyatt Technology, LLC and its three operating subsidiaries, Wyatt Technology Europe GmbH, Wyatt Technology France and Wyatt Technology UK Ltd. (collectively, “Wyatt”), for a total purchase price of \$1.3 billion in cash. Wyatt is a pioneer in innovative light scattering and field-flow fractionation instruments, software, accessories, and services. The acquisition will expand Waters’ portfolio and increase exposure to large molecule applications. The Company financed this transaction with a combination of cash on its balance sheet and borrowings under its revolving credit facility. The Company’s financial results for the twelve months ended March 30, 2024 include the financial results of Wyatt. The Company’s financial results for the twelve months ended April 1, 2023 do not include any of the financial results of Wyatt since the closing of the Wyatt acquisition occurred in the second fiscal quarter of 2023.

## [Table of Contents](#)

### Financial Overview

The Company's operating results are as follows for the three months ended March 30, 2024 and April 1, 2023 (in thousands, except per share data):

	Three Months Ended		
	March 30, 2024	April 1, 2023	% change
Revenues:			
Product sales	\$ 376,151	\$ 436,457	(14)
Service sales	260,688	248,217	5
Total net sales	636,839	684,674	(7)
Costs and operating expenses:			
Cost of sales	261,786	284,380	(8)
Selling and administrative expenses	174,536	181,956	(4)
Research and development expenses	44,595	42,691	4
Purchased intangibles amortization	11,834	1,479	700
Litigation provision	10,242	—	*
Operating income	133,846	174,168	(23)
Operating income as a % of sales	21.0 %	25.4 %	
Other income, net	2,259	1,388	*
Interest expense, net	(21,249 )	(10,383 )	105
Income before income taxes	114,856	165,173	(30)
Provision for income taxes	12,660	24,250	(48)
Net income	\$ 102,196	\$ 140,923	(27)
Net income per diluted common share	\$ 1.72	\$ 2.38	(28)

\*\* Percentage not meaningful

The Company's net sales decreased 7% in the first quarter of 2024, as compared to the first quarter of 2023, with foreign currency translation decreasing total sales growth by 1%. The decrease in first quarter sales was primarily due to lower customer demand for our products across most major regions, except for sales in Europe, which increased 1% and the U.S., which were flat and benefited from Wyatt sales contributions. The decline in customer demand was primarily attributed to our customers delaying the purchase of our instrument systems as they remained cautious about capital spending entering 2024. The Wyatt acquisition increased sales growth by 3% for the first quarter of 2024. In addition, the Company's first quarter of 2024 had one less calendar day than the first quarter of 2023.

Instrument system sales decreased 20% in the first quarter of 2024 primarily driven by weaker customer demand in most regions of the world. The instrument system sales decline was broad-based across all of our instrument systems, especially for our mass spectrometry instrument systems, where the decline was significantly greater. Our mass spectrometry system sales are higher priced instrument systems that are significantly impacted by the timing of funding our academic and government customers receive. In addition, the Wyatt acquisition increased instrument system sales growth by 5% in the first quarter of 2024. Foreign currency translation did not impact instrument system sales growth in the first quarter of 2024.

Recurring revenues (combined sales of precision chemistry consumables and services) increased 3% in the first quarter of 2024, with foreign currency translation decreasing sales growth by 1%. Service revenues increased 5% in the first quarter of 2024, with Wyatt contributing 2% to service revenue growth in the quarter. Chemistry sales decreased 1% in the first quarter of 2024 and were impacted by the lower customer demand in China for our products. Excluding the impact of China, the Company's chemistry sales increased 3% in the first quarter of 2024.

Operating income was \$134 million in the first quarter of 2024, a decrease of 23% as compared to \$174 million in the first quarter of 2023. The decrease in operating income was primarily due to lower sales volume and the following expenses: Wyatt acquisition-related retention expense and purchased intangible amortization, which

10%; severance-related costs associated with a workforce reduction primarily in China, which added 5%, settlement provisions and related costs, which added 6%. These costs were partially offset by a 5% reduction related to the Wyatt acquisition diligence incurred in the first quarter of 2023.

---

## [Table of Contents](#)

The Company generated \$263 million and \$197 million of net cash from operating activities in the first quarter of 2024 and 2023, respectively, with the \$66 million increase being attributable to lower annual incentive bonus expense and an improvement in working capital in the current year. Net cash used in investing activities included expenditures related to property, plant, equipment and software capitalization of \$29 million and \$34 million in the first quarter of 2024 and 2023, respectively.

## Results of Operations

### Sales by Geography

Geographic sales information is presented below for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	Three Months Ended		
	March 30, 2024	April 1, 2023	% change
Net Sales:			
Asia:			
China	\$ 85,745	\$ 116,065	(26)
Japan	35,547	46,494	(24)
Asia Other	86,267	90,522	(5)
Total Asia	207,559	253,081	(18)
Americas:			
United States	202,839	202,305	—
Americas Other	38,332	44,116	(13)
Total Americas	241,171	246,421	(2)
Europe	188,109	185,172	2
Total net sales	\$ 636,839	\$ 684,674	(7)

Geographically, the Company's sales decline in the first quarter of 2024 was broad-based across most markets except for Europe, which increased 2%, and the U.S., which was flat and benefited from Wyatt sales contracts. The decline in sales can be attributed to the lower demand for our instrument systems and chemistry products, which delayed the purchase of these products. Foreign currency translation decreased sales growth by 3% in Asia and increased sales growth by 2% in Europe in the first quarter of 2024.

### Sales by Trade Class

Net sales by customer class are presented below for the three months ended March 30, 2024 and April 1, 2023 (in thousands):

	Three Months Ended		
	March 30, 2024	April 1, 2023	% change
Pharmaceutical	\$ 374,207	\$ 384,898	(3)
Industrial	195,334	209,650	(7)
Academic and government	67,298	90,126	(25)
Total net sales	\$ 636,839	\$ 684,674	(7)

---

## [Table of Contents](#)

During the first quarter of 2024, sales to pharmaceutical customers decreased 3%, as growth in Europe was offset by weakness across most major regions, with foreign currency translation decreasing pharmaceutical sales growth by 1% and Wyatt contributing 4% to the Company's pharmaceutical sales growth. Combined sales to industrial customers, which include material characterization, food, environmental and fine chemical markets, decreased 1% in the first quarter of 2024, with foreign currency translation decreasing sales growth by 1% and Wyatt contributing 2% to industrial sales growth.

Sales to our academic and government customers are highly dependent on when institutions receive funding to purchase our instrument systems and, as such, sales can vary significantly from period to period. Our combined sales to academic and government customers decreased 25% in the first quarter of 2024, with foreign currency translation decreasing sales by 2% and Wyatt contributing 3% to the Company's academic and government sales growth. The overall decline in sales of 25% to our academic and government customers in the first quarter of 2024 compared to the 38% increase in academic and government sales in the first quarter of 2023, which represents a two-year annual growth rate of 1%.

### Waters Products and Services Net Sales

Net sales for Waters products and services were as follows for the three months ended March 30, 2024 and April 1, 2023 (dollars in thousands):

	Three Months Ended			
	March 30, 2024	% of Total	April 1, 2023	% of Total
Waters instrument systems	\$ 191,259	34 %	\$ 244,211	41 %
Chemistry consumables	134,207	24 %	133,515	22 %
Total Waters product sales	325,466	58 %	377,726	63 %
Waters service	236,433	42 %	224,349	37 %
Total Waters net sales	\$ 561,899	100 %	\$ 602,075	100 %

Waters products and service sales decreased 7% in the first quarter of 2024, with the effect of foreign currency translation decreasing sales growth by 1%. The Wyatt acquisition increased Waters products and service sales by approximately 4% in the quarter. Waters instrument system sales decreased 22% in the first quarter of 2024 due to weaker customer demand. Waters service sales increased 5% in the first quarter of 2024 due to higher sales volume billing in all regions except for China, partially offset by the negative impact from foreign currency translation. Total Waters net sales decreased service sales growth by 1%.

### TA Product and Services Net Sales

Net sales for TA products and services were as follows for the three months ended March 30, 2024 and April 1, 2023 (dollars in thousands):

	Three Months Ended			
	March 30, 2024	% of Total	April 1, 2023	% of Total
TA instrument systems	\$ 50,685	68 %	\$ 58,731	71 %
TA service	24,255	32 %	23,868	29 %
Total TA net sales	\$ 74,940	100 %	\$ 82,599	100 %

TA sales declined 9% in the first quarter of 2024 due to lower customer demand for TA products in all regions except for Latin America and India. Foreign currency translation decreased TA sales growth by 1% in the quarter.

### Cost of Sales

Cost of sales decreased by 8% in the first quarter 2024, primarily due to lower sales volume, changes in lower freight costs. Cost of sales is affected by many factors, including, but not limited to, foreign currency product mix, product costs of instrument systems and amortization of software platforms. At current foreign exchange rates, the Company expects foreign currency translation to decrease gross profit during 2024.

---

## [Table of Contents](#)

### Selling and Administrative Expenses

Selling and administrative expenses decreased 4% in the first quarter of 2024 primarily due to the \$8 million decrease in costs related to the Wyatt acquisition diligence incurred in the first quarter of 2023 and the decrease in costs resulting from lower headcount from the reductions in workforce that occurred in March 2024. These decreases were partially offset by the increase of \$6 million in Wyatt acquisition-related retention expense and the \$8 million increase in severance-related costs in connection with a reduction in workforce. In the first quarter of 2024, the Company's reduction in workforce, primarily impacting China employees, as result of the significant sales volume decrease in China's sales over the last year. This workforce reduction impacted approximately 2% of the Company's workforce worldwide. The effect of foreign currency translation did not have a significant impact on selling and administrative expenses in the first quarter of 2024.

As a percentage of net sales, selling and administrative expenses were 27.4% and 26.6% for the first quarter of 2024 and 2023, respectively.

### Research and Development Expenses

Research and development expenses increased 4% in the first quarter of 2024, primarily driven by costs associated with the development of new product and technology initiatives as well as \$2 million in Wyatt acquisition-related retention expense. The impact of foreign currency exchange increased expenses by 3% in the first quarter of 2024.

### Purchased Intangibles Amortization

The increase in purchased intangible amortization of \$10 million in the first quarter of 2024 can be attributed to the Wyatt acquisition intangible assets.

### Litigation Provisions

The Company recorded \$10 million of patent litigation settlement provisions and related costs in the first quarter of 2024.

### Interest Expense, net

Net interest expense in the first quarter of 2024 increased \$11 million, which can be primarily attributed to additional borrowings by the Company to fund the Wyatt acquisition.

### Provision for Income Taxes

The four principal jurisdictions in which the Company manufactures are the U.S., Ireland, the U.K. and Singapore, where the statutory tax rates were 21%, 12.5%, 25% and 17%, respectively, as of March 30, 2024. The Company also benefits from the Development and Expansion Incentive in Singapore that provides a concessionary income tax rate of 5% on certain types of income for the period April 1, 2021 through March 31, 2026. The effect of applying the concessionary tax rate rather than the statutory tax rate to income from qualifying activities in Singapore increased the Company's net income by \$2 million and \$3 million and increased the Company's net income per diluted share by \$0.01 and \$0.02 for the first quarter of 2024 and 2023, respectively.

The Company's effective tax rate for the first quarter of 2024 and 2023 was 11.0% and 14.7%, respectively. The Company's tax provision includes a \$1 million and a \$2 million income tax benefit related to stock-based compensation in the first quarter of 2024 and 2023, respectively. The remaining differences between the effective tax rates can primarily be attributed to the impact of discrete tax benefits in the current year and to differences in the proportionate share of pre-tax income recognized in jurisdictions with different effective tax rates.

Effective in 2024, various foreign jurisdictions began implementing aspects of the guidance issued by the OECD for Economic Co-operation and Development related to the new Pillar Two system of global minimum tax. The changes in tax law did not have a material impact on the Company's financial position, results of operations or cash flows for the first quarter of 2024. The Company continues to monitor the adoption of the Pillar Two rules in various jurisdictions.





---

## [Table of Contents](#)

### Liquidity and Capital Resources

#### Condensed Consolidated Statements of Cash Flows (in thousands):

	Three Months Ended	
	March 30, 2024	April 1, 2023
Net income	\$ 102,196	\$ 140,923
Depreciation and amortization	48,514	31,154
Stock-based compensation	10,913	12,805
Deferred income taxes	4,453	(5,078 )
Change in accounts receivable	62,592	44,047
Change in inventories	(28,309 )	(42,621 )
Change in accounts payable and other current liabilities	(18,418 )	(71,257 )
Change in deferred revenue and customer advances	85,901	77,206
Other changes	(4,972 )	9,572
Net cash provided by operating activities	262,870	196,751
Net cash used in investing activities	(29,744 )	(34,406 )
Net cash used in financing activities	(292,176 )	(159,211 )
Effect of exchange rate changes on cash and cash equivalents	1,264	2,407
(Decrease) increase in cash and cash equivalents	<u>\$ (57,786 )</u>	<u>\$ 5,541</u>

#### Cash Flow from Operating Activities

Net cash provided by operating activities was \$263 million and \$197 million during the first quarter of 2024 and 2023, respectively. The decrease in 2024 operating cash flow was primarily a result of lower net income and higher depreciation and amortization, offset by higher cash collections and lower annual incentive bonus payments in 2024 compared to 2023. Changes within net cash provided by operating activities include the following significant changes in the uses of net cash provided by operating activities, aside from the changes in net income:

- The changes in accounts receivable were primarily attributable to timing of payments made by customers and timing of sales. Days sales outstanding was 89 days at March 30, 2024 and 91 days at April 1, 2023.
- The increase in inventory can primarily be attributed to higher material costs.
- Net cash provided from deferred revenue and customer advances results from annual increases in service contracts as a higher installed base of customers renew annual service contracts.
- Other changes were attributable to variation in the timing of various provisions, expenditures on research and development, income taxes and accruals in other current assets, other assets and other liabilities.

#### Cash Flow from Investing Activities

Net cash used in investing activities totaled \$30 million and \$34 million in the first quarter of 2024 and 2023, respectively. Additions to fixed assets and capitalized software were \$29 million and \$34 million in the first three months of 2024 and 2023, respectively.

During the first three months of 2024 and 2023, the Company purchased \$1 million of investments, while no investments matured, and were used for financing activities described below.

#### Cash Flow from Financing Activities

The Company entered into a credit agreement in September 2021 governing the Company's five-year, \$1 revolving credit facility that matures in September 2026. On March 3, 2023, the Company entered into a amend such credit agreement. The 2023 Amendment increased the borrowing capacity by \$200 million to borrowing capacity of \$2.0 billion. As of March 30, 2024, the Company had a total of \$2.1 billion in outstanding debt, which consisted of \$1.3 billion in outstanding senior unsecured notes and \$750 million borrowed under the credit agreement. The Company's net debt borrowings decreased by \$300 million and \$95 million during the three months ended March 30, 2024 and April 1, 2023, respectively.

---

## **Table of Contents**

As of March 30, 2024, the Company has entered into interest rate cross-currency swap derivative agreements with durations up to three years with a notional value \$625 million to hedge the variability in the movement of currency exchange rates on a portion of its euro-denominated and yen-denominated net asset investment. Upon entering into these agreements, the Company lowered net interest expense by approximately \$3 million in the quarter of 2024 and 2023. The Company anticipates that these swap agreements will lower net interest expense by approximately \$8 million in 2024.

In December 2023, the Company's Board of Directors authorized the extension of its existing share repurchase program through January 21, 2025. The Company's remaining authorization is \$1.0 billion. During the three months ended April 1, 2023, the Company repurchased 0.2 million shares of the Company's outstanding common stock at a cost of \$58 million under the Company's share repurchase program. The Company did not make any open market repurchases in 2024. In addition, the Company repurchased \$13 million and \$11 million of common stock upon the vesting of restricted stock units during the three months ended March 30, 2024 and April 1, 2023, respectively. The Company believes that it has the financial flexibility to fund these share repurchases, as well as to invest in research, technology and business acquisitions, given current cash levels and debt borrowing capacity, it has temporarily suspended its share repurchases due to its recent acquisition of Wyatt.

The Company received \$14 million and \$2 million of proceeds from the exercise of stock options and the sale of shares pursuant to the Company's employee stock purchase plan during the first three months of 2024 and 2023, respectively.

The Company had cash, cash equivalents and investments of \$338 million as of March 30, 2024. The majority of the Company's cash and cash equivalents are generated from foreign operations, with \$305 million held by the Company's subsidiaries at March 30, 2024, of which \$239 million was held in currencies other than U.S. dollars.

## **Contractual Obligations, Commercial Commitments, Contingent Liabilities and Dividends**

A summary of the Company's contractual obligations and commercial commitments is included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 2, 2024. The Company reviewed its contractual obligations and commercial commitments as of March 30, 2024 and determined that there were no material changes outside the ordinary course of business from the information set forth in the Company's Annual Report on Form 10-K.

From time to time, the Company and its subsidiaries are involved in various litigation matters arising in the ordinary course of business. The Company believes that it has meritorious arguments in its current litigation matters and that any outcome, either individually or in the aggregate, will not be material to the Company's financial position or results of operations.

During fiscal year 2024, the Company expects to contribute a total of approximately \$3 million to \$6 million to its defined benefit plans.

The Company has not paid any dividends and has no plans, at this time, to pay any dividends in the future.

## **Critical Accounting Policies and Estimates**

In the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 27, 2024, the Company's most critical accounting policies and estimates upon which its financial performance depends were identified as those relating to revenue recognition, valuation of long-lived assets, intangible assets, goodwill, income taxes, uncertain tax positions and business combinations and asset acquisitions. The Company reviewed its policies and determined that those policies remain the Company's most critical accounting policies as of the three months ended March 30, 2024. The Company did not make any changes in those policies during the three months ended March 30, 2024.

---

## **Table of Contents**

### **New Accounting Pronouncements**

Please refer to Note 13, Recent Accounting Standard Changes and Developments, in the Condensed Notes to Consolidated Financial Statements.

### **Special Note Regarding Forward-Looking Statements**

This Quarterly Report on Form 10-Q, including the information incorporated by reference herein, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements of historical fact may be deemed forward-looking statements. You can identify these forward-looking statements by the use of the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “may”, “will”, “will be”, “intends”, “suggests”, “appears”, “estimates”, “projects”, “should” and similar expressions, whether in the affirmative. These forward-looking statements are subject to various risks and uncertainties, many of which are beyond the control of the Company, including, and without limitation:

- foreign currency exchange rate fluctuations potentially affecting translation of the Company’s non-U.S. operating results, particularly when a foreign currency weakens against the U.S. dollar;
- current global economic, sovereign and political conditions and uncertainties, including the effect of a proposed tariff or trade regulations, as well as other new or changed domestic and foreign laws and policies, changes in inflation and interest rates, the impacts and costs of war, in particular the ongoing conflicts between Russia and Ukraine and in the Middle East, and the possibility of escalation resulting in new geopolitical and regulatory instability and the Chinese government tightening of restrictions on procurement by government-funded customers;
- the Company’s ability to access capital, maintain liquidity and service the Company’s debt in various conditions;
- risks related to the effects of any pandemic on our business, financial condition, results of operations and prospects;
- changes in timing and demand for the Company’s products among the Company’s customers and market sectors, particularly as a result of fluctuations in their expenditures or ability to obtain financing;
- the ability to realize the expected benefits related to the Company’s various cost-saving initiatives, workforce reductions and organizational restructurings;
- the introduction of competing products by other companies and loss of market share, as well as price pressures from competitors and/or customers;
- changes in the competitive landscape as a result of changes in ownership, mergers and acquisitions and consolidation among the Company’s competitors;
- regulatory, economic and competitive obstacles to new product introductions, lack of acceptance of new products and inability to grow organically through innovation;
- rapidly changing technology and product obsolescence;
- risks associated with previous or future acquisitions, strategic investments, joint ventures and other business combinations, including risks associated with achieving the anticipated financial results and operational synergies, contingent purchase price payments; and expansion of our business into new or developing markets;
- risks associated with unexpected disruptions in operations;
- failure to adequately protect the Company’s intellectual property, infringement of intellectual property rights of third parties and inability to obtain licenses on commercially reasonable terms;

---

## **Table of Contents**

- the Company's ability to acquire adequate sources of supply and its reliance on outside contractors for certain components and modules, as well as disruptions to its supply chain;
- risks associated with third-party sales intermediaries and resellers;
- the impact and costs of changes in statutory or contractual tax rates in jurisdictions in which the Company operates as well as shifts in taxable income among jurisdictions with different effective tax rates; the outcome of ongoing and future tax examinations and changes in legislation affecting the Company's tax rate;
- the Company's ability to attract and retain qualified employees and management personnel;
- risks associated with cybersecurity and technology, including attempts by third parties to defeat security measures of the Company and its third-party partners;
- increased regulatory burdens as the Company's business evolves, especially with respect to the Food and Drug Administration and U.S. Environmental Protection Agency, among others, and in connection with government contracts;
- regulatory, environmental and logistical obstacles affecting the distribution of the Company's products; the completion of purchase order documentation and the ability of customers to obtain letters of credit and financing alternatives;
- risks associated with litigation and other legal and regulatory proceedings; and
- the impact and costs incurred from changes in accounting principles and practices.

Certain of these and other factors are discussed under the heading "Risk Factors" under Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on March 29, 2024. Actual results or events could differ materially from the plans, intentions and expectations disclosed in our forward-looking statements, whether because of these factors or for other reasons. All forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are expressly qualified in their entirety by the cautionary statements included in this report. Except as required by law, the Company does not assume a duty to update any forward-looking statements.

### **Item 3: Quantitative and Qualitative Disclosures About Market Risk**

The Company is exposed to the risk of interest rate fluctuations from the investments of cash generated from its operations. Investments with maturities greater than 90 days are classified as investments and are held primarily in U.S. dollar-denominated treasury bills and commercial paper, bank deposits and corporate debt securities. As of March 30, 2024, the Company estimates that a hypothetical adverse change of 100 basis points across all investments would not have a material effect on the fair market value of its portfolio.

The Company is also exposed to the risk of exchange rate fluctuations. The Company maintains cash balances in various operating accounts in excess of federally insured limits, and in foreign subsidiary accounts in currencies other than the U.S. dollar. As of March 30, 2024 and December 31, 2023, \$305 million out of \$338 million and \$305 million out of \$396 million, respectively, of the Company's total cash, cash equivalents and investments were held in subsidiaries. In addition, \$239 million out of \$338 million and \$233 million out of \$396 million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at March 30, 2024 and December 31, 2023, respectively. As of March 30, 2024, the Company had no holdings in auction rate securities or commercial mortgage-backed securities by structured investment vehicles.

Assuming a hypothetical adverse change of 10% in year-end exchange rates (a strengthening of the U.S. dollar), the market value of the Company's cash, cash equivalents and investments held in currencies other than the U.S. dollar as of March 30, 2024 would decrease by approximately \$24 million, of which the majority would be recorded as a non-currency translation in other comprehensive income within stockholders' equity.

There have been no other material changes in the Company's market risk during the three months ended 2024. For information regarding the Company's market risk, refer to Item 7A of Part II of the Company's on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 27, 2024.

---

## [Table of Contents](#)

### **Item 4: Controls and Procedures**

#### **Evaluation of Disclosure Controls and Procedures**

The Company's chief executive officer and chief financial officer (principal executive officer and principal financial officer), with the participation of management, evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, the Company's chief executive officer and chief financial officer concluded that the Company's disclosure controls and procedures were effective as of March 30, 2024, to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, is (1) that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in its reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

#### **Changes in Internal Control Over Financial Reporting**

No change was identified in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 30, 2024 that has materially affected or is reasonably likely to materially affect, the Company's internal control over financial reporting.

### **Part II: Other Information**

#### **Item 1: Legal Proceedings**

There have been no material changes in the Company's legal proceedings during the three months ended March 30, 2024 as described in Item 3 of Part I of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 27, 2024, other than the \$10 million patent litigation settlement and related costs recorded in the three months ended March 30, 2024.

#### **Item 1A: Risk Factors**

Information regarding risk factors of the Company is set forth under the heading "Risk Factors" under Part II of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 27, 2024. The Company reviewed its risk factors as of March 30, 2024 and determined that there were no material changes from the ones set forth in the Form 10-K. Note, however, the discussion of certain risk factors under the subheading "Special Note Regarding Forward-Looking Statements" in Part I, Item 2 of this Quarterly Report on Form 10-Q. These risks are not the only ones facing the Company. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial may have a material adverse effect on the Company's business, financial condition and operating results.

#### **Item 2: Unregistered Sales of Equity Securities and Use of Proceeds**

##### **Purchases of Equity Securities by the Issuer**

In January 2019, the Company's Board of Directors authorized the Company to repurchase up to \$4 billion of its outstanding common stock in open market or private transactions over a two-year period. This program was subsequently extended and the remaining amounts available under the pre-existing authorization. In December 2020, the Company's Board of Directors authorized the extension of the share repurchase program through January 21, 2023. In December 2022, the Company's Board of Directors amended and extended this repurchase program's term by one year such that it would expire on January 21, 2024 and increased the total authorization level to \$4.8 billion, an increase of \$750 million. In December 2023, the Company's Board of Directors authorized the extension of the share repurchase program through January 21, 2025. As of March 30, 2024, the Company had repurchased an aggregate of 15.2 million shares at a cost of approximately \$1.0 billion under the January 2019 repurchase program and had a total of \$1.0 billion authorized for future repurchases. The number and timing of these purchases, if any, will depend on our stock price and market and business conditions and other factors.

---

## [Table of Contents](#)

<u>Period</u>	<u>Total Number of Shares Purchased (1)</u>	<u>Average Price Paid per Share</u>	<u>Total Number of Shares Purchased as Part of Publicly Announced Programs</u>	<u>Maxim Value That M Purcha the I</u>
January 1, 2024 to January 27, 2024	—	\$ —	—	\$
January 28, 2024 to February 24, 2024	9	\$ 329.26	—	\$
February 25, 2024 to March 30, 2024	30	\$ 335.87	—	\$
Total	39	\$ 334.34	—	\$

- (1) The Company repurchased approximately 39,000 shares of common stock at a cost of \$13 million resulting from the vesting of restricted stock during the three months ended March 30, 2024.

### **Item 5: Other Information**

Insider Trading Arrangements and Related Disclosures

None.



---

## **Table of Contents**

### **Item 6: Exhibits**

<b>Exhibit Number</b>	<b>Description of Document</b>
31.1	<a href="#">Chief Executive Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.(*)</a>
31.2	<a href="#">Chief Financial Officer Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.(*)</a>
32.1	<a href="#">Chief Executive Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(*)</a>
32.2	<a href="#">Chief Financial Officer Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.(*)</a>
101	The following materials from Waters Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 30, 2024, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets (unaudited), (ii) the Consolidated Statements of Operations (unaudited), (iii) the Consolidated Statements of Comprehensive Income (unaudited), (iv) the Consolidated Statements of Cash Flows (unaudited) and (v) Condensed Notes to Consolidated Financial Statements (unaudited).
104	Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101).

(\*) This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation by reference in any filing, except to the extent the Company specifically incorporates it by reference.

---

[Table of Contents](#)

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WATERS CORPORATION

/s/ Amol Chaubal

Amol Chaubal  
Senior Vice President and Chief Financial Officer  
(Principal Financial Officer)  
(Principal Accounting Officer)

Date: May 7, 2024